516 patents
Utility
Fused pyrimidine derivatives as A2A/A2B inhibitors
16 Jan 24
Xiaozhao Wang, Heeoon Han, Matthew S. McCammant, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Le Zhao
Filed: 27 Jan 21
Utility
Heterocyclic compounds as immunomodulators
16 Jan 24
Kaijiong Xiao, Fenglei Zhang, Liangxing Wu, Wenqing Yao
Filed: 19 Nov 20
Utility
Benzothiazole compounds and uses thereof
9 Jan 24
Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
Filed: 16 Nov 20
Utility
Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
9 Jan 24
The present application provides dihydropyrido[2,3-d]pyrimidone inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Alexander Sokolsky, Liangxing Wu, Wenqing Yao
Filed: 10 Jun 21
Utility
Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
9 Jan 24
This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.
Dengjin Wang, Daniel Carper, Zhongjiang Jia, Bo Shen, Joseph A. Sclafani, Robert Wilson, Jiacheng Zhou, Osama Suleiman, Mark Wright
Filed: 5 Nov 21
Utility
Heterocyclic compounds as immunomodulators
9 Jan 24
Neil Lajkiewicz, Liangxing Wu, Wenqing Yao
Filed: 22 Nov 22
Utility
Salts and crystalline forms of a PD-1/PD-L1 inhibitor
9 Jan 24
This application relates to solid forms and salt forms of the PD-1/PD-L1 inhibitor 4,4′-(((((2,2′-dichloro-[1,1′-biphenyl]-3,3′-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid), including processes of preparation thereof, where the solid forms and salt forms are useful in the treatment of various diseases including infectious diseases and cancer.
Zhongjiang Jia, Shili Chen, Yi Li, Timothy Martin, Bo Shen, Naijing Su, Jiacheng Zhou, Qun Li
Filed: 10 Nov 20
Utility
1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
4 Jan 24
The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
Andrew P. Combs, Thomas P. Maduskuie, JR., Nikoo Falahatpisheh
Filed: 31 May 23
Utility
Topical Ruxolitinib for Treating Lichen Planus
28 Dec 23
The present disclosure relates to topical treatment of lichen planus (LP) using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Aaron R. MANGOLD, Ahmad B. NAIM
Filed: 1 Oct 21
Utility
Combination Therapy of ANTI-PD-1 Active Agent, ANTI-TIM-3 Active Agent, and ANTI-LAG-3 Active Agent for Treating Cancer
28 Dec 23
The present disclosure provides a combination therapy which comprises: (i) an active agent that binds PD-1 (e.g., an anti-PD-1 antibody), (ii) an active agent that binds TIM-3 (e.g., an anti-TIM-3 antibody), and/or (iii) an active agent that binds LAG-3 (e.g., an anti-LAG-3 antibody).
Paul E. Hoyle, Zhiwan Dong, Thomas Condamine, Nithya Srinivasan, John E. Janik, Kevin N. Heller
Filed: 6 Jun 23
Utility
Process of Preparing a PD-1/PD-L1 Inhibitor
21 Dec 23
The present invention relates to processes of preparing PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3′-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or salts thereof, related synthetic intermediates, and salts of the intermediates, where the PD-1/PD-L1 inhibitor is useful in the treatment of various diseases including infectious diseases and cancer.
Jiacheng Zhou, Shili Chen, Zhongjiang Jia, Yi Li, Qiyan Lin, Pingli Liu, Yongchun Pan, Timothy Martin, Bo Shen, Chongsheng Eric Shi, Naijing Su, Yongzhong Wu, Michael Xia
Filed: 31 Aug 23
Utility
Tricyclic Triazolo Compounds As DGK Inhibitors
14 Dec 23
The present application provides tricyclic triazolo compounds that modulate the activity of diacylglycerol kinase (DGK), which are useful in the treatment of various diseases, including cancer.
Joshua Hummel, Liana Hie, Jacob J. Lacharity, Xiaolei Li, Sharada Manns, Ding-Quan Qian, Xiaozhao Wang, Bo Wei, Meizhong Xu
Filed: 7 Jun 23
Utility
PD-L1/STING Conjugates and Methods of Use
14 Dec 23
The present application relates to conjugates of STING agonists and small molecule modulators of the PD-1/PD-L1 protein/protein interaction, as well as methods of treating cancer using the conjugates.
Liangxing Wu, Zhenwu Li, Wenqing Yao
Filed: 3 Jan 23
Utility
Solid Forms of Jak Inhibitor and Process of Preparing the Same
14 Dec 23
The present disclosure is related to solid forms of ruxolitinib di-hydrate and ruxolitinib free base, process of preparing the same, and compositions comprising the same.
Zhongjiang Jia, Weiguo Liu, Pingli Liu, David Meloni, Yongchun Pan, Jiacheng Zhou, Travis Houston
Filed: 14 Jun 23
Utility
Imidazopyridazine compounds and uses thereof
12 Dec 23
Jun Pan, Yu Bai, Liangxing Wu, Wenqing Yao
Filed: 10 Jun 21
Utility
Substituted tricyclic compounds as FGFR inhibitors
12 Dec 23
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Liangxing Wu, Colin Zhang, Chunhong He, Liang Lu, Wenqing Yao
Filed: 2 Jun 21
Utility
JAK1 pathway inhibitors for the treatment of cytokine-related disorders
5 Dec 23
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).
Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass
Filed: 19 Jul 21
Utility
Combination therapy for treatment of myeloproliferative neoplasms
5 Dec 23
The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a BET protein inhibitor, 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-1,4-benzoxazin-3(4H)-one, wherein the combination is unexpectedly synergistic.
Matthew Stubbs, Phillip C. Liu
Filed: 2 Jun 21
Utility
Heterocyclylamines as PI3K inhibitors
21 Nov 23
Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Brent Douty, Song Mei
Filed: 18 Jul 22
Utility
Topical Treatment of Vitiligo
16 Nov 23
The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Kathleen BUTLER, Jim LEE, Kang SUN, Fiona KUO, Michael HOWELL
Filed: 16 Sep 21